U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H22BrN3O2
Molecular Weight 344.247
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BROMOPRIDE

SMILES

CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC

InChI

InChIKey=GIYAQDDTCWHPPL-UHFFFAOYSA-N
InChI=1S/C14H22BrN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)

HIDE SMILES / InChI

Description

Bromopride is a dopamine D2 receptor blocker. Bromopride exerts is a gastrointestinal prokinetic exploited clinically for the management of motor disorders of the upper gastrointestinal tract, including functional dyspepsia, gastric stasis of various origins and emesis.

CNS Activity

CNS Active
3,913

Originator

Soc. d'Etudes Sci. de l'Ile-de-France
2

Approval Year

Unknown
139,594

Targets

Primary TargetPharmacologyConditionPotency
Dopamine D2 receptor
297
Antagonist
2,778
cholinesterase activity
5
Inhibitor
8,297

Conditions

ConditionModalityTargetsHighest PhaseProduct
Dyspepsia
11
 Primary
Approved
8,429
Bromopan

PubMed

Patents

US3177252
2

Sample Use Guides

In Vivo Use Guide
Capsules: 40-60 mg/day Oral solution: 40-60 mg/day (adults), 0.5-1 mg/kg (children)
Route of Administration: Oral
In Vitro Use Guide
Bromopride effects on cholinesterase activity in plasma, striatum, duodenum and ileum of adult male rats were measured for drug concentrations ranging from 0.006 to 3.134 microM. Bromopride can inhibit cholinesterase activity in all tissues studied,
ACTIVE MOIETY
Structure of BROMOPRIDE
SALT/SOLVATE (PARENT)
Structure of BROMOPRIDE HYDROCHLORIDE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966